The NCI-MATCH study reported an ORR of 38% (90% CI: 22.9, 54.9; P < 0.0001) with dabrafenib plus trametinib in patients with BRAF V600E/D/R/K mutation-positive solid tumors, lymphomas or MM whose disease had progressed on at least one standard therapy20. This evidence concerns the gene BRAF and Miyoshi myopathy.